請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78613完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李財坤(Tsai-Kun Li) | |
| dc.contributor.author | Yen-Che Lee | en |
| dc.contributor.author | 李儼哲 | zh_TW |
| dc.date.accessioned | 2021-07-11T15:07:20Z | - |
| dc.date.available | 2024-08-28 | |
| dc.date.copyright | 2019-08-28 | |
| dc.date.issued | 2019 | |
| dc.date.submitted | 2019-08-13 | |
| dc.identifier.citation | Azarova, A. M., Y. L. Lyu, C. P. Lin, Y. C. Tsai, J. Y. Lau, J. C. Wang and L. F. Liu (2007). 'Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.' Proc Natl Acad Sci U S A 104(26): 11014-11019.
Bachmann, I. M., O. J. Halvorsen, K. Collett, I. M. Stefansson, O. Straume, S. A. Haukaas, H. B. Salvesen, A. P. Otte and L. A. Akslen (2006). 'EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.' Journal of Clinical Oncology 24(2): 268-273. Bodor, C., C. O'Riain, D. Wrench, J. Matthews, S. Iyengar, H. Tayyib, M. Calaminici, A. Clear, S. Iqbal, H. Quentmeier, H. G. Drexler, S. Montoto, A. T. Lister, J. G. Gribben, A. Matolcsy and J. Fitzgibbon (2011). 'EZH2 Y641 mutations in follicular lymphoma.' Leukemia 25(4): 726-729. Bracken, A. P., N. Dietrich, D. Pasini, K. H. Hansen and K. Helin (2006). 'Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions.' Genes Dev 20(9): 1123-1136. Bracken, A. P., D. Pasini, M. Capra, E. Prosperini, E. Colli and K. Helin (2003). 'EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.' Embo Journal 22(20): 5323-5335. Bray, F., J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre and A. Jemal (2018). 'Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.' CA Cancer J Clin 68(6): 394-424. Brown, J. L., D. Mucci, M. Whiteley, M. L. Dirksen and J. A. Kassis (1998). 'The Drosophila Polycomb group gene pleiohomeotic encodes a DNA binding protein with homology to the transcription factor YY1.' Mol Cell 1(7): 1057-1064. Bruchovsky, N. and J. D. Wilson (1968). 'The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro.' J Biol Chem 243(8): 2012-2021. Cano, L. Q., D. N. Lavery and C. L. Bevan (2013). 'Mini-review: Foldosome regulation of androgen receptor action in prostate cancer.' Mol Cell Endocrinol 369(1-2): 52-62. Cao, Q., J. Yu, S. M. Dhanasekaran, J. H. Kim, R. S. Mani, S. A. Tomlins, R. Mehra, B. Laxman, X. Cao, J. Yu, C. G. Kleer, S. Varambally and A. M. Chinnaiyan (2008). 'Repression of E-cadherin by the polycomb group protein EZH2 in cancer.' Oncogene 27(58): 7274-7284. Cao, R. and Y. Zhang (2004). 'SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex.' Molecular Cell 15(1): 57-67. Capranico, G., S. Tinelli, C. A. Austin, M. L. Fisher and F. Zunino (1992). 'Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development.' Biochim Biophys Acta 1132(1): 43-48. Chen, G., A. C. Huang, W. Zhang, G. Zhang, M. Wu, W. Xu, Z. Yu, J. Yang, B. Wang, H. Sun, H. Xia, Q. Man, W. Zhong, L. F. Antelo, B. Wu, X. Xiong, X. Liu, L. Guan, T. Li, S. Liu, R. Yang, Y. Lu, L. Dong, S. McGettigan, R. Somasundaram, R. Radhakrishnan, G. Mills, Y. Lu, J. Kim, Y. H. Chen, H. Dong, Y. Zhao, G. C. Karakousis, T. C. Mitchell, L. M. Schuchter, M. Herlyn, E. J. Wherry, X. Xu and W. Guo (2018). 'Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.' Nature 560(7718): 382-386. Cowell, I. G., Z. Sondka, K. Smith, K. C. Lee, C. M. Manville, M. Sidorczuk-Lesthuruge, H. A. Rance, K. Padget, G. H. Jackson, N. Adachi and C. A. Austin (2012). 'Model for MLL translocations in therapy-related leukemia involving topoisomerase IIbeta-mediated DNA strand breaks and gene proximity.' Proc Natl Acad Sci U S A 109(23): 8989-8994. de la Torre Gomez, C., R. V. Goreham, J. J. Bech Serra, T. Nann and M. Kussmann (2018). ''Exosomics'-A Review of Biophysics, Biology and Biochemistry of Exosomes With a Focus on Human Breast Milk.' Front Genet 9: 92. Dillon, S. C., X. Zhang, R. C. Trievel and X. Cheng (2005). 'The SET-domain protein superfamily: protein lysine methyltransferases.' Genome Biol 6(8): 227. Downes, C. S., D. J. Clarke, M. Mullinger, J. F. Gimenezabian, A. M. Creighton and R. T. Johnson (1994). 'A Topoisomerase Ii-Dependent G2 Cycle Checkpoint in Mammalian-Cells.' Nature 372(6505): 467-470. F.F.G., R. (1998). Testosterone: An overview of biosynthesis, transport, metabolism and nongenomic actions. Testosterone. B. H. M. Nieschlag E. Springer, Berlin, Heidelberg, . Gaytan de Ayala Alonso, A., L. Gutierrez, C. Fritsch, B. Papp, D. Beuchle and J. Muller (2007). 'A genetic screen identifies novel polycomb group genes in Drosophila.' Genetics 176(4): 2099-2108. Gonzalez, M. E., H. M. Moore, X. Li, K. A. Toy, W. Huang, M. S. Sabel, K. M. Kidwell and C. G. Kleer (2014). 'EZH2 expands breast stem cells through activation of NOTCH1 signaling.' Proceedings of the National Academy of Sciences of the United States of America 111(8): 3098-3103. Grino, P. B., J. E. Griffin and J. D. Wilson (1990). 'Testosterone at High-Concentrations Interacts with the Human Androgen Receptor Similarly to Dihydrotestosterone.' Endocrinology 126(2): 1165-1172. Haffner, M. C., M. J. Aryee, A. Toubaji, D. M. Esopi, R. Albadine, B. Gurel, W. B. Isaacs, G. S. Bova, W. Liu, J. Xu, A. K. Meeker, G. Netto, A. M. De Marzo, W. G. Nelson and S. Yegnasubramanian (2010). 'Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.' Nat Genet 42(8): 668-675. He, B., J. A. Kemppainen, J. J. Voegel, H. Gronemeyer and E. M. Wilson (1999). 'Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain.' J Biol Chem 274(52): 37219-37225. Holm, C., T. Goto, J. C. Wang and D. Botstein (1985). 'DNA Topoisomerase-Ii Is Required at the Time of Mitosis in Yeast.' Cell 41(2): 553-563. Huang, K.-C., H. Gao, E. F. Yamasaki, D. R. Grabowski, S. Liu, L. L. Shen, K. K. Chan, R. Ganapathi and R. M. Snapka (2001). 'Topoisomerase II Poisoning by ICRF-193.' Journal of Biological Chemistry 276(48): 44488-44494. Huang, Y., X. Jiang, X. Liang and G. Jiang (2018). 'Molecular and cellular mechanisms of castration resistant prostate cancer.' Oncol Lett 15(5): 6063-6076. Huggins, C. and C. V. Hodges (1972). 'Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.' CA Cancer J Clin 22(4): 232-240. Joannides, M., A. N. Mays, A. R. Mistry, S. K. Hasan, A. Reiter, J. L. Wiemels, C. A. Felix, F. L. Coco, N. Osheroff, E. Solomon and D. Grimwade (2011). 'Molecular pathogenesis of secondary acute promyelocytic leukemia.' Mediterr J Hematol Infect Dis 3(1): e2011045. Joshi, P., E. A. Carrington, L. Wang, C. S. Ketel, E. L. Miller, R. S. Jones and J. A. Simon (2008). 'Dominant alleles identify SET domain residues required for histone methyltransferase of Polycomb repressive complex 2.' J Biol Chem 283(41): 27757-27766. Ju, B. G., V. V. Lunyak, V. Perissi, I. Garcia-Bassets, D. W. Rose, C. K. Glass and M. G. Rosenfeld (2006). 'A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription.' Science 312(5781): 1798-1802. Jung, H. Y., S. Jun, M. Lee, H. C. Kim, X. Wang, H. Ji, P. D. McCrea and J. I. Park (2013). 'PAF and EZH2 induce Wnt/beta-catenin signaling hyperactivation.' Mol Cell 52(2): 193-205. Kim, E., M. Kim, D. H. Woo, Y. Shin, J. Shin, N. Chang, Y. T. Oh, H. Kim, J. Rheey, I. Nakano, C. Lee, K. M. Joo, J. N. Rich, D. H. Nam and J. Lee (2013). 'Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.' Cancer Cell 23(6): 839-852. Kim, J., Y. Lee, X. Lu, B. Song, K. W. Fong, Q. Cao, J. D. Licht, J. C. Zhao and J. Yu (2018). 'Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.' Cell Rep 25(10): 2808-2820 e2804. Ku, M., R. P. Koche, E. Rheinbay, E. M. Mendenhall, M. Endoh, T. S. Mikkelsen, A. Presser, C. Nusbaum, X. Xie, A. S. Chi, M. Adli, S. Kasif, L. M. Ptaszek, C. A. Cowan, E. S. Lander, H. Koseki and B. E. Bernstein (2008). 'Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains.' PLoS Genet 4(10): e1000242. Kusunoki, H., T. Takeuchi and T. Kohno (2009). 'Solution structure of the AT-rich interaction domain of Jumonji/JARID2.' Proteins 76(4): 1023-1028. Labrie, F. (2004). 'Adrenal androgens and intracrinology.' Semin Reprod Med 22(4): 299-309. Lee, S. T., Z. M. Li, Z. L. Wu, M. Aau, P. Y. Guan, R. K. M. Karuturi, Y. C. Liou and Q. Yu (2011). 'Context-Specific Regulation of NF-kappa B Target Gene Expression by EZH2 in Breast Cancers.' Molecular Cell 43(5): 798-810. Lewis, E. B. (1978). 'A gene complex controlling segmentation in Drosophila.' Nature 276(5688): 565-570. Lilja, H., D. Ulmert and A. J. Vickers (2008). 'Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.' Nat Rev Cancer 8(4): 268-278. Lubahn, D. B., D. R. Joseph, P. M. Sullivan, H. F. Willard, F. S. French and E. M. Wilson (1988). 'Cloning of human androgen receptor complementary DNA and localization to the X chromosome.' Science 240(4850): 327-330. Lyu, Y. L., C. P. Lin, A. M. Azarova, L. Cai, J. C. Wang and L. F. Liu (2006). 'Role of topoisomerase IIbeta in the expression of developmentally regulated genes.' Mol Cell Biol 26(21): 7929-7941. Lyu, Y. L. and J. C. Wang (2003). 'Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase IIbeta.' Proc Natl Acad Sci U S A 100(12): 7123-7128. Madabhushi, R. (2018). 'The Roles of DNA Topoisomerase IIbeta in Transcription.' Int J Mol Sci 19(7). Mangelsdorf, D. J., C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, P. Chambon and R. M. Evans (1995). 'The nuclear receptor superfamily: the second decade.' Cell 83(6): 835-839. Mani, R. S., M. A. Amin, X. Li, S. Kalyana-Sundaram, B. A. Veeneman, L. Wang, A. Ghosh, A. Aslam, S. G. Ramanand, B. J. Rabquer, W. Kimura, M. Tran, X. Cao, S. Roychowdhury, S. M. Dhanasekaran, N. Palanisamy, H. A. Sadek, P. Kapur, A. E. Koch and A. M. Chinnaiyan (2016). 'Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer.' Cell Rep 17(10): 2620-2631. Margueron, R., G. H. Li, K. Sarma, A. Blais, J. Zavadil, C. L. Woodcock, B. D. Dyniacht and D. Reinberg (2008). 'Ezh1 and Ezh2 Maintain Repressive Chromatin through Different Mechanisms.' Molecular Cell 32(4): 503-518. McEwan, I. J. (2004). 'Molecular mechanisms of androgen receptor-mediated gene regulation: structure-function analysis of the AF-1 domain.' Endocr Relat Cancer 11(2): 281-293. Mihaly, J., R. K. Mishra and F. Karch (1998). 'A conserved sequence motif in Polycomb-response elements.' Mol Cell 1(7): 1065-1066. Morin, R. D., N. A. Johnson, T. M. Severson, A. J. Mungall, J. H. An, R. Goya, J. E. Paul, M. Boyle, B. W. Woolcock, F. Kuchenbauer, D. Yap, R. K. Humphries, O. L. Griffith, S. Shah, H. Zhu, M. Kimbara, P. Shashkin, J. F. Charlot, M. Tcherpakov, R. Corbett, A. Tam, R. Varhol, D. Smailus, M. Moksa, Y. J. Zhao, A. Delaney, H. Qian, I. Birol, J. Schein, R. Moore, R. Holt, D. E. Horsman, J. M. Connors, S. Jones, S. Aparicio, M. Hirst, R. D. Gascoyne and M. A. Marra (2010). 'Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.' Nature Genetics 42(2): 181-U124. Muhlberger, N., K. Boskovic, M. D. Krahn, K. E. Bremner, W. Oberaigner, H. Klocker, W. Horninger, G. Sroczynski and U. Siebert (2017). 'Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.' BMC Public Health 17(1): 596. Park, I. and H. K. Avraham (2006). 'Cell cycle-dependent DNA damage signaling induced by ICRF-193 involves ATM, ATR, CHK2, and BRCA1.' Exp Cell Res 312(11): 1996-2008. Perlmutter, M. A. and H. Lepor (2007). 'Androgen deprivation therapy in the treatment of advanced prostate cancer.' Rev Urol 9 Suppl 1: S3-8. Piunti, A. and A. Shilatifard (2016). 'Epigenetic balance of gene expression by Polycomb and COMPASS families.' Science 352(6290): aad9780. Pommier, Y., E. Leo, H. Zhang and C. Marchand (2010). 'DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.' Chem Biol 17(5): 421-433. Pommier, Y., Y. Sun, S. N. Huang and J. L. Nitiss (2016). 'Roles of eukaryotic topoisomerases in transcription, replication and genomic stability.' Nat Rev Mol Cell Biol 17(11): 703-721. Qu, Y., B. Dai, D. Ye, Y. Kong, K. Chang, Z. Jia, X. Yang, H. Zhang, Y. Zhu and G. Shi (2015). 'Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer.' Sci Rep 5: 7654. Rea, S., F. Eisenhaber, D. O'Carroll, B. D. Strahl, Z. W. Sun, M. Schmid, S. Opravil, K. Mechtler, C. P. Ponting, C. D. Allis and T. Jenuwein (2000). 'Regulation of chromatin structure by site-specific histone H3 methyltransferases.' Nature 406(6796): 593-599. Saini, S. (2016). 'PSA and beyond: alternative prostate cancer biomarkers.' Cell Oncol (Dordr) 39(2): 97-106. Sauvageau, M. and G. Sauvageau (2010). 'Polycomb Group Proteins: Multi-Faceted Regulators of Somatic Stem Cells and Cancer.' Cell Stem Cell 7(3): 299-313. Schuettengruber, B., D. Chourrout, M. Vervoort, B. Leblanc and G. Cavalli (2007). 'Genome regulation by polycomb and trithorax proteins.' Cell 128(4): 735-745. Shaffer, P. L., A. Jivan, D. E. Dollins, F. Claessens and D. T. Gewirth (2004). 'Structural basis of androgen receptor binding to selective androgen response elements.' Proc Natl Acad Sci U S A 101(14): 4758-4763. Shi, B., J. Liang, X. Yang, Y. Wang, Y. Zhao, H. Wu, L. Sun, Y. Zhang, Y. Chen, R. Li, Y. Zhang, M. Hong and Y. Shang (2007). 'Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.' Mol Cell Biol 27(14): 5105-5119. Squazzo, S. L., H. O'Geen, V. M. Komashko, S. R. Krig, V. X. Jin, S. W. Jang, R. Margueron, D. Reinberg, R. Green and P. J. Farnham (2006). 'Suz12 binds to silenced regions of the genome in a cell-type-specific manner.' Genome Res 16(7): 890-900. Suzman, D. L. and E. S. Antonarakis (2014). 'Castration-resistant prostate cancer: latest evidence and therapeutic implications.' Ther Adv Med Oncol 6(4): 167-179. Tan, M. H., J. Li, H. E. Xu, K. Melcher and E. L. Yong (2015). 'Androgen receptor: structure, role in prostate cancer and drug discovery.' Acta Pharmacol Sin 36(1): 3-23. Thomas, M. J. and E. Seto (1999). 'Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key?' Gene 236(2): 197-208. Tomlins, S. A., N. Palanisamy, J. Siddiqui, A. M. Chinnaiyan and L. P. Kunju (2012). 'Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.' Arch Pathol Lab Med 136(8): 935-946. Trotter, K. W., H. A. King and T. K. Archer (2015). 'Glucocorticoid Receptor Transcriptional Activation via the BRG1-Dependent Recruitment of TOP2beta and Ku70/86.' Mol Cell Biol 35(16): 2799-2817 . Tsutsui, K., K. Tsutsui, O. Hosoya, K. Sano and A. Tokunaga (2001). 'Immunohistochemical analyses of DNA topoisomerase II isoforms in developing rat cerebellum.' J Comp Neurol 431(2): 228-239. Tsutsui, K., K. Tsutsui, K. Sano, A. Kikuchi and A. Tokunaga (2001). 'Involvement of DNA topoisomerase IIbeta in neuronal differentiation.' J Biol Chem 276(8): 5769-5778. Uemura, T., H. Ohkura, Y. Adachi, K. Morino, K. Shiozaki and M. Yanagida (1987). 'DNA Topoisomerase-Ii Is Required for Condensation and Separation of Mitotic Chromosomes in S-Pombe.' Cell 50(6): 917-925. Varambally, S., S. M. Dhanasekaran, M. Zhou, T. R. Barrette, C. Kumar-Sinha, M. G. Sanda, D. Ghosh, K. J. Pienta, R. G. A. B. Sewalt, A. P. Otte, M. A. Rubin and A. M. Chinnaiyan (2002). 'The polycomb group protein EZH2 is involved in progression of prostate cancer.' Nature 419(6907): 624-629. Visser, H. P. J., M. J. Gunster, H. C. Kluin-Nelemans, E. M. M. Manders, F. M. Raaphorst, C. J. L. M. Meijer, R. Willemze and A. P. Otte (2001). 'The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma.' British Journal of Haematology 112(4): 950-958. Wang, J. C. (1998). 'Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine.' Quarterly Reviews of Biophysics 31(2): 107-144. Wang, J. C. (2002). 'Cellular roles of DNA topoisomerases: a molecular perspective.' Nat Rev Mol Cell Biol 3(6): 430-440. Wang, M. C., L. A. Valenzuela, G. P. Murphy and T. M. Chu (1979). 'Purification of a human prostate specific antigen.' Invest Urol 17(2): 159-163. Watanabe, M., K. Tsutsui, K. Tsutsui and Y. Inoue (1994). 'Differential expressions of the topoisomerase II alpha and II beta mRNAs in developing rat brain.' Neurosci Res 19(1): 51-57. Whiteside, T. L. (2016). 'Exosomes and tumor-mediated immune suppression.' J Clin Invest 126(4): 1216-1223. Wong, R. H., I. Chang, C. S. Hudak, S. Hyun, H. Y. Kwan and H. S. Sul (2009). 'A role of DNA-PK for the metabolic gene regulation in response to insulin.' Cell 136(6): 1056-1072. Wu, H., H. Zeng, A. Dong, F. Li, H. He, G. Senisterra, A. Seitova, S. Duan, P. J. Brown, M. Vedadi, C. H. Arrowsmith and M. Schapira (2013). 'Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.' PLoS One 8(12): e83737. Xu, C., C. Bian, W. Yang, M. Galka, H. Ouyang, C. Chen, W. Qiu, H. Liu, A. E. Jones, F. MacKenzie, P. Pan, S. S. Li, H. Wang and J. Min (2010). 'Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2).' Proc Natl Acad Sci U S A 107(45): 19266-19271. Xu, K. X., Z. J. Wu, A. C. Groner, H. S. H. S. He, C. M. Cai, R. T. Lis, X. Q. Wu, E. C. Stack, M. Loda, T. Liu, H. Xu, L. Cato, J. E. Thornton, R. I. Gregory, C. Morrissey, R. L. Vessella, R. Montironi, C. Magi-Galluzzi, P. W. Kantoff, S. P. Balk, X. S. Liu and M. Brown (2012). 'EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent.' Science 338(6113): 1465-1469. Yang, X., W. Li, E. D. Prescott, S. J. Burden and J. C. Wang (2000). 'DNA topoisomerase IIbeta and neural development.' Science 287(5450): 131-134. Zannas, A. S., T. Wiechmann, N. C. Gassen and E. B. Binder (2016). 'Gene-Stress-Epigenetic Regulation of FKBP5: Clinical and Translational Implications.' Neuropsychopharmacology 41(1): 261-274. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78613 | - |
| dc.description.abstract | EZH2在生理上的角色一般被認知作為PRC2複合體的一部分，主要負責甲基轉移的酵素活性功能。PRC2複合體可在組蛋白三第27個離胺酸位點上進行三甲基修飾(H3K27me3)，抑制目標基因的表現。而在最近的研究指出EZH2在閹割抗性前列腺癌(CRPC)中第21個絲氨酸被磷酸化(pS21-EZH2)的情形較雄性激素依賴性前列腺癌(ADPC)來得高，且這樣的磷酸化會使得EZH2脫離PRC2複合體，從抑制基因表現的角色，轉化為促進基因表現，我們稱之為「EZH2基因表現轉換(EZH2-mediated gene expression switch)」。有鑑於過往研究指出，在雄性激素受體(androgen receptor, AR)所調控的基因表現中，需要人類拓樸異構酶hTop2β參與，由hTop2β造成DNA斷裂的訊號後誘發後續轉錄啟動的機制。故本篇我們想要探討的是在EZH2基因表現轉換中，hTop2β是否也會藉由形成DNA斷裂去誘導轉錄啟動。首先，我們進行細胞感受性的確認，並證明pS21-EZH2在CRPC中有較高的表現量。再者，我們發現在CRPC細胞中，solo genes的表現量明顯較高，且利用hTop2β的抑制劑ICRF-193，我們觀察到屬於solo genes的FKBP5的表現會受到ICRF-193明顯的抑制，顯示hTop2β可能參與在solo genes的表現中。下一步我們想看hTop2β所造成的DNA斷裂生成的情形，發現在雄性激素DHT的刺激下，會有明顯的γH2A.X的生成，且會被ICRF-193所抑制，代表雄性激素的刺激會活化hTop2β並造成DNA的斷裂，藉以活化基因表現。利用染色質免疫沉澱法，我們也發現了hTop2β確實可以結合至solo genes的啟動子上，進一步證明hTop2β參與在solo genes的表現中。最後，肇因於胞外小體(exosomes)相關重要性在近年被逐漸發現，並參與在細胞溝通與腫瘤微環境(tumor microenvironment)調控中，我們也發現CRPC細胞可以將pS21-EZH2分泌至胞外小體，說明pS21-EZH2可藉由胞外小體到達其他細胞或組織，可能在影響前列腺癌進展成CRPC的過程中有舉足輕重的角色。綜合以上，我們觀察到hTop2β參與在EZH2的基因表現轉換中，且EZH2的基因調控轉變在CRPC較為旺盛。現今對於前列腺癌的治療主要依賴賀爾蒙治療、手術與放射線治療，但以上療法並無法延緩前列腺的進程。根據我們的研究發現hTop2β在EZH2基因表現轉換中的參與，我們推測原本做為臨床上後線治療策略的hTop2β抑制劑，也許其早期運用，可以減緩或預防前列腺癌轉變為閹割抗性前列腺癌，藉以提高患者的預後，與癌症治癒的可能性。 | zh_TW |
| dc.description.abstract | Enhancer of zeste homolog 2 (EZH2) was first found as an enzymatic protein subunit responsible for methyltransferase activity in Polycomb repressive complex 2 (PRC2). PRC2 acts as repressor of transcription through generation of H3K27me3 marks. Interestingly, it was found that phosphorylated EZH2 at serine 21 residue (pS21-EZH2) was upregulated in CRPC, and EZH2 phosphorylation cause functional switch of EZH2, from transcriptional repressor to activator, which could activate solo genes expression, and it was known as EZH2 gene expression switch. We found that solo genes expression was higher in CRPC, and hTop2β inhibitor ICRF-193 could attenuate the expression of solo genes in CRPC cell lines. Furthermore, we found DNA breaks formation induced by androgen treatment could be attenuated by ICRF-193, which suggested that these breaks were generated by hTop2β. Moreover, we demonstrated the interaction between pS21-EZH2 and hTop2β, which indicated that EZH2-mediated gene expression may be conducted through cooperation with hTop2β. In addition, as exosomes became important targets for cancer research, we found pS21-EZH2 could be secreted to exosomes which indicated that pS21-EZH2 could be transported through exosomes, which may contribute to alter the tumor microenvironment. In conclusion, we found hTop2β could involve in EZH2-mediated gene expression switch, in this regard, hTop2β inhibitors may be able to prevent the prostate cancer progression from ADPC to CRPC. But now in clinical cancer management, first line treatments of prostate cancer were hormone therapy, surgery and radiation, hTop2β inhibitors were not the primary choices for cancer treatment. But those treatments were not able to prevent cancer progression from CRPC. Basing on our research, we speculate early usage of hTop2β inhibitors clinically may contribute to prevention of prostate cancer progression to CRPC. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-11T15:07:20Z (GMT). No. of bitstreams: 1 ntu-108-R06445123-1.pdf: 2186697 bytes, checksum: 94f6c7cec26c39aac59877c1c701c7b8 (MD5) Previous issue date: 2019 | en |
| dc.description.tableofcontents | 口試委員審定書............................................I
致謝....................................................II 中文摘要................................................III ABSTRACT.................................................V CONTENTS...............................................VII INTRODUCTIONS............................................1 1. Prostate cancer..................................1 2. Androgen receptor signaling......................2 2.1 Androgen receptor....................................2 2.2 Activation of AR.....................................3 2.3 Prostate cancer androgen dependency..................3 2.4 Castration-resistant prostate cancer(CRPC)...........4 3. Polycomb repressive complex......................5 3.1 Polycomb repressive complex 2 (PRC2).................5 3.2 Enhancer of zeste homolog 2 (EZH2)...................7 3.3 EZH2-mediated gene expression switch.................9 4. Topoisomerases and Transcription................11 4.1 Topoisomerases......................................11 4.2 Roles of hTop2β in transcription....................12 4.3 hTop2β and cancer...................................14 SPECIFIC AIM............................................16 MATERIALS AND METHODS...................................17 Cell culture............................................17 Antibodies and chemical reagents........................17 RNA extraction..........................................18 Reverse transcription...................................18 Real-time quantitative PCR..............................19 Western blot analysis...................................19 Immunofluorescence assay................................19 Coimmunoprecipitation...................................20 Exosomes isolation......................................20 RESULTS.................................................22 1. Gene subset analysis of EZH2 solo genes, ensemble genes and AR responsive genes...........................22 2. Selection of appropriate experimental cell line models..................................................23 3. Elevated EZH2 phosphorylation at serine 21 residue in CRPC cells...........................................24 4. Expression of solo genes were higher in CRPC than ADPC....................................................25 5. AR responsive and solo genes expression level could be attenuated by treatment of hTop2β inhibitor ICRF-193.....................................................26 6. Formation of γH2A.X under DHT treatment.........26 7. pS21-EZH2 could interact with hTop2β directly...28 8. Secretion of pS21-EZH2 into exosomes............29 DISCUSSIONS.............................................32 FIGURES AND TABLES......................................36 Table 1. Primer list....................................36 Figure 1. There were 2.5 % overlap between AR genes and solo genes..............................................37 Figure 2. The induction of PSA along DHT treatment indicated appropriate sensitivity of the cell lines.....38 Figure 3. Elevated phosphorylated EZH2 at serine 21 residue in CRPC.........................................40 Figure 4. Expression of solo genes was higher in CRPC than ADPC....................................................42 Figure 5. The expression of solo genes could be attenuated by ICRF-193 treatment...................................43 Figure 6. Androgen treatment could induce DNA double-stranded breaks mediated by hTop2β......................45 Figure 7. hTop2β could interact with pS21-EZH2 directly.49 Figure 8. Secretion of pS21-EZH2 into exosomes but not SUZ12...................................................51 REFERENCES..............................................53 | |
| dc.language.iso | en | |
| dc.subject | 胞外小體 | zh_TW |
| dc.subject | 閹割抗性前列腺癌 | zh_TW |
| dc.subject | 人類第二型拓樸異構?β | zh_TW |
| dc.subject | 第21絲氨酸鄰酸化EZH2 | zh_TW |
| dc.subject | 去氧核醣核酸斷裂 | zh_TW |
| dc.subject | exosomes | en |
| dc.subject | human Topoisomerase 2β (hTop2β) | en |
| dc.subject | Enhancer of zeste homolog 2 (EZH2) | en |
| dc.subject | DNA break | en |
| dc.subject | Castration-resistant prostate cancer (CRPC) | en |
| dc.title | 探討前列腺癌進程中hTop2β-DNA-PKcs複合體在EZH2造成的基因表現轉換所扮演的角色 | zh_TW |
| dc.title | Potential role of hTop2β-DNA-PKcs complex in EZH2-mediated gene expression switch during prostate cancer progression | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 107-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 李明學(Ming-Shyue Lee),賴逸儒(I-Rue Lai) | |
| dc.subject.keyword | 閹割抗性前列腺癌,人類第二型拓樸異構?β,第21絲氨酸鄰酸化EZH2,去氧核醣核酸斷裂,胞外小體, | zh_TW |
| dc.subject.keyword | Castration-resistant prostate cancer (CRPC),human Topoisomerase 2β (hTop2β),Enhancer of zeste homolog 2 (EZH2),DNA break,exosomes, | en |
| dc.relation.page | 61 | |
| dc.identifier.doi | 10.6342/NTU201903266 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2019-08-14 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| dc.date.embargo-lift | 2024-08-28 | - |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-108-R06445123-1.pdf 未授權公開取用 | 2.14 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。